You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Austin, Texas 78744

  • Schizophrenia

Purpose:

The purposes of this study are: - To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and - To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.


Criteria:

Inclusion Criteria: - Healthy male or female subjects of non-childbearing potential Exclusion Criteria: - Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).


NCT ID:

NCT00150215


Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer


Backup Contact:

N/A


Location Contact:

Austin, Texas 78744
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.